Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04195256
Other study ID # 091819
Secondary ID
Status Recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date March 11, 2020
Est. completion date December 2024

Study information

Verified date February 2023
Source Lawson Health Research Institute
Contact Naveen Poonai, MD
Phone 5196858500
Email naveen.poonai@lhsc.on.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Orthopedic injuries comprise more than 10% of ED visits in children and 25 to 50% of children will sustain a fracture before age 16 years. Distal radius fractures account for 20-32% of fractures in children, making them the most common fracture type. Between 20 and 40% of extremity fractures in children require a closed reduction, often necessitating procedural sedation and analgesia (PSA). Intravenous (IV) ketamine is the most commonly used sedative agent used to perform a closed reduction. However, children rate IV insertion as the most painful hospital experience, second only to the injury itself. IV insertion can be more technically difficult in children because of smaller veins and lack of cooperation, often leading to multiple IV attempts. A combination of intranasal (IN) dexmedetomidine plus ketamine (IN Ketodex) may provide effective sedation for children undergoing a closed reduction without the distress and pain related to IV insertion. A less painful experience has been found to correlate with child satisfaction which may reduce caregiver anxiety and improve the therapeutic relationship with the health care team. This study is a multi-centre, two-arm, randomized, blinded, controlled, non-inferiority trial designed to test the hypothesis that IN Ketodex is non-inferior to intravenous (IV) ketamine with respect to depth of sedation as measured using the Pediatrics Sedation State Scale (PSSS).


Description:

Intranasal medications may offer a technically easier and pain-free approach to procedural sedation (PSA); one that may have widespread applicability in patients with needle-phobia, difficult IV access, resource-limited settings, or when experience placing an IV is limited. Although IN ketamine has been found to be effective for fracture pain, procedural pain, anesthetic pre-induction, and diagnostic imaging, a recent shortage of this agent in the highest concentration of 100 mg/mL has severely limited out ability to study its effectiveness and consequent clinical uptake. Our research team conducted three systematic reviews of randomized trials of IN ketamine and IN dexmedetomidine in children undergoing painful procedures. The latter review included 18 trials (n=2128) of children age 1 month to 14 years. Our review found that IN dexmedetomidine, dosed from 1-4 mcg/kg, was well tolerated and superior to conventional sedatives (midazolam and chloral hydrate) in providing adequate sedation to 525/669 (78.5%) children. A number of studies found that IN dexmedetomidine was in fact superior to IN ketamine. Surendar et al. found that IN dexmedetomidine at 1.5 mcg/kg facilitated successful sedation in 18/21 (86%) of children undergoing dental procedures and was more effective than IN ketamine 5 mg/kg. Gyanesh et al. found that the proportion of children with satisfactory IV sedation was greater with IN dexmedetomidine 1 mcg/kg compared to IN ketamine 5 mg/kg [47/52 (90%) versus 43/52 (83%), respectively]. Mostafa et al. found that IN dexmedetomidine 1 mcg/kg was more effective at facilitating caregiver separation than IN ketamine 5 mg/kg or IN midazolam 0.2 mg/kg [30/32 (92%) versus 22/32 (69%) versus 28/32 (88%), respectively]. Moreover, a combination of dexmedetomidine and ketamine appeared to be superior than either agent alone. Qiao et al. found that IN dexmedetomidine 2 mcg/kg and oral ketamine 3 mg/kg in children undergoing IV insertion was superior to both IN dexmedetomidine 2.5 mcg/kg and oral ketamine 6 mg/kg alone (80.1% versus 47.6% versus 68.3%, respectively). Bhat et al. found that a combination of IN dexmedetomidine 1 mcg/kg and IN ketamine 2 mg/kg versus IN dexmedetomidine 1 mcg/kg alone facilitated greater acceptance of face mask (67% versus 52%, respectively) and greater tolerance of caregiver separation (93% versus 89%, respectively) (38). We also found evidence that higher doses of IN dexmedetomidine were more effective. More specifically, at the higher end of the dosing range (1-4 mcg/kg), IN dexmedetomidine 3 mcg/kg was superior to IN ketamine 7 mg/kg; providing adequate sedation to 25/29 (86.3%) versus 23/29 (79.4%) of children undergoing IV insertion, respectively. A dose-finding study of IN dexmedetomidine in children < 3 years who were post-operative from cardiac surgery and were undergoing transthoracic echocardiography found an optimal median effective dose of 3.3 mcg/kg (range 2.72-3.78 mcg/kg). Taken together, our review suggests that the most effective and tolerable intranasal agent for procedural sedation for fracture reduction is a combination of IN dexmedetomidine 4 mcg/kg and IN ketamine 2-3 mg/kg. There is ample and ongoing evidence of suboptimal management for procedural pain in children, a high frequency of orthopedic injuries requiring IV placement for PSA, and a lack of evidence to support the use of strategies that reduce the pain of IVs. However, there are no studies that have shown the effectiveness of IN ketamine for fracture reduction in children. In order to provide robust evidence supporting an alternate approach that precludes the need for an IV in children undergoing PSA, the investigators propose a study to answer the important research question: In children presenting to the ED with an orthopedic injury requiring PSA, does IN Ketodex provide as effective sedation as IV ketamine?


Recruitment information / eligibility

Status Recruiting
Enrollment 400
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 4 Years to 17 Years
Eligibility INCLUSION CRITERIA General Criteria 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Deemed by treating physician to require procedural sedation Specific criteria 1. Children presenting to the paediatric EDs of participating sites age 4-17 years 2. Weighing up to and including 60 kg 3. Painful procedure including one of the following: - Forearm fracture - Metacarpal or phalangeal fracture - Dislocation of a shoulder or elbow - Type II supracondylar fracture 4. Closed reduction expected to not require more than one dose of IV sedative sedation medication (as determined by the procedure physician and not including cast or splint application). 5. Both nares are fully patent. 6. Fracture is minimally or not shortened EXCLUSION CRITERIA 1. Previous hypersensitivity reaction to ketamine or dexmedetomidine including rash, difficulty breathing, hypotension, apnea, or laryngospasm; 2. Suspected globe rupture; 3. Concomitant traumatic brain injury with intracranial hemorrhage; 4. Uncontrolled hypertension; 5. Nasal bone deformity or septal deviation; 6. Poor English or French fluency in the absence of native language interpreter; 7. American Society of Anesthesiologists (ASA) class 3 or greater; 8. Previous diagnosis of schizophrenia or active psychosis as per the treating physician 9. Neuro-cognitive impairment that precludes informed consent, assent, or ability to self-report pain and satisfaction; 10. More than one fracture or dislocation requiring reduction; 11. Hemodynamic compromise as per the treating physician; 12. Glasgow coma score < 15; 13. Previous sedation with ketamine or hematoma block within 24 hours; 14. Fracture is comminuted or associated with a dislocation; 15. Participant has undergone a hematoma block within 24 hours; 16. Obstructive sleep apnea 17. Previous enrollment in the trial; 18. Suspected pregnancy 19. Congenital heart disease or known cardiac dysrhythmia 20. Known or suspected hepatic impairment 21. Known renal insufficiency 22. Uncorrected mineralocorticoid deficiency

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
IN Ketodex (D4K2)
Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 4 mcg/kg (0.04 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 2 mg/kg (0.04 mL/kg) of 50 mg/mL solution, maximum of 200 mg (4 mL) (D4K2), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
IN Ketodex (D3K3)
Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 3 mcg/kg (0.03 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 3 mg/kg (0.06 mL/kg) of 50 mg/mL solution, maximum of 300 mg (6 mL) (D3K3), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
IN Ketodex (D2K4)
Dexmedetomidine (Pfizer, Kirkland, Quebec), single-dose, 2 mcg/kg (0.02 mL/kg) of 100 mcg/mL solution, maximum of 200 mcg (2 mL) THEN Ketamine (Sandoz, Mississauga, Ontario), single dose, 4 mg/kg (0.08 mL/kg) of 50 mg/mL solution, maximum of 400 mg (8 mL) (D2K4), both delivered intranasally using a mucosal atomizer device (MAD) and divided to both nares AND 0.9% normal saline 0.03 mL/kg delivered intravenously to a maximum of 2 mL
IV Ketamine
Ketamine, single dose, 1.5 mg/kg (0.03 mL/kg) of 50 mg/mL solution delivered intravenously, to a maximum of 100 mg (2 mL) AND two aliquots of 0.9% normal saline in 3 possible combinations: (i) 0.04 mL/kg (max 2 mL) then 0.04 mL/kg (max 4 mL) (placebo D4K2), (ii) 0.03 mL/kg (max 2 mL) then 0.06 mL/kg (max 6 mL) (placebo D3K3), (iii) 0.02 mL/kg (max 2 mL) then 0.08 mL/kg (max 8 mL) (placebo D2K4), delivered intranasally using a MAD and divided to both nares

Locations

Country Name City State
Canada Stollery Children's Hospital Edmonton Alberta
Canada McMaster Children's Hospital Hamilton Ontario
Canada London Health Sciences Centre London Ontario
Canada Children's Hospital of Eastern Ontario Ottawa Ontario
Canada BC Children's Hospital Vancouver British Columbia
Canada Winnipeg Children's Hospital Winnipeg Ontario

Sponsors (1)

Lead Sponsor Collaborator
Naveen Poonai

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Length of stay due to procedural sedation Defined as the time interval from the first pair of IN sprays/IV dose to discharge, reflective of the time difference associated with different routes of administration. Through study completion in the ED (4 hours)
Other Duration of procedure Defined as time of the first pair of IN sprays to the end of cast or splint application (closed reduction) in minutes Through study completion in the ED (4 hours)
Other Caregiver, participant, bedside nurse or respiratory therapist, and physician satisfaction Satisfaction will be measured using a visual analog scale (VAS) when the participant is deemed ready for discharge. The following questions will be posed: How satisfied were you with your child's sedation? (Caregiver if at bedside), How happy were you with your sleep? (Participant), or How satisfied were you with the level of sedation in your patient? (Sedating physician & nurse/respiratory therapist as per who is at bedside). Through study completion in the ED (4 hours)
Other Nasal irritation Discomfort associated with nasal sprays will be assessed by the research nurse using the Faces Pain Scale -Revised (FPS-R) when the participant is deemed ready for discharge. The FPS-R is a self-report measure scored as either 0,2,4,6,8,10, with increasing numbers indicating greater pain. Through study completion in the ED (4 hours)
Other Volume of IN intervention received / Volume of IN intervention intended Volume of IN intervention received / Volume of IN intervention intended Through study completion in the ED (4 hours)
Other Adjunctive IV therapy and medications The number of participants requiring an IV for therapy unrelated to sedation (eg. analgesics, antibiotics, antiemetics, fluids) will be recorded. Through study completion in the ED (4 hours)
Other Pre-sedation Pain Will be recorded by the research nurse from the participant using the Faces Pain Scale - Revised (FPS-R) immediately prior to the first pair of intranasal sprays Through study completion in the ED (4 hours)
Other Patient Preference The following question will be posed to the child: "If you were to be put to sleep again for an injury, what would you prefer, an intravenous needle or nasal sprays (choose one)?" Through study completion in the ED (4 hours)
Other Exploratory subgroup analyses A planned subgroup analyses to determine whether the between group difference in adequacy of sedation is dependent on (i) pain score prior to sedation. Through study completion in the ED (4 hours)
Primary Adequate sedation Adequate is defined as fulfillment of all three of the following criteria:
(i) A Pediatric Sedation State Scale (PSSS) score of 2 or 3 for the duration of the procedure (defined for closed reduction as the interval of time from the first application of traction or manipulation of the injured limb for the purpose of anatomical realignment to the last application of a realigning force). The PSSS is scored from 0 to 5 in discrete integer values every 15 seconds. A score of 4 or 5 indicates under-sedation and a score of 0 or 1 indicates over sedation.
(ii) No additional medication is given during the procedure for the purpose of sedation.
(iii) The patient did not actively resist, cry, or require physical restraint for completion of the closed reduction.
Through study completion in the ED (4 hours)
Secondary Length of stay Defined as the time recorded in the medical record between triage and discharge. Through study completion in the ED (4 hours)
Secondary Time to wakening This will be defined as the duration of time between the first pair of IN sprays and the first PSSS score of > 3 post-closed reduction. Through study completion in the ED (4 hours)
Secondary Adverse effects Adverse effects as defined by Health Canada reporting standards Through study completion in the ED and up to 72 hours post-discharge
See also
  Status Clinical Trial Phase
Withdrawn NCT04470895 - Impact of Drugs on the Risk of Falls in the Fracture Department of the Paris Saint-Joseph Hospital Group
Recruiting NCT02635022 - Fragility Fracture Liaison Service and Anti-osteoporosis Medication Monitoring Service Study
Unknown status NCT02013986 - Effects of Etomidate on Postoperative Circadian Rhythm Changes of Salivary Cortisol in Children Phase 4
Terminated NCT01248182 - Bone to Skin Thickness Study: Obese Versus Normal Population N/A
Recruiting NCT00969839 - NovaLign Intramedullary Fixation System (IFS) for the Treatment of Humeral Fractures Phase 4
Completed NCT00520442 - Acute Pediatric Fracture Analgesia Study N/A
Completed NCT00115180 - Racial and Ethnic Disparities in Acute Pain Control N/A
Not yet recruiting NCT06402292 - Surgical Treatment of Osteoarticular Infections Using Bioactive Bone Substitute N/A
Recruiting NCT04947722 - The PREVENT Trial: a Pragmatic Cluster Randomized Controlled Trial of a Multifaceted Fracture Prevention Model for Long-term Care N/A
Recruiting NCT06107699 - The CHARM Study-Coordinating Transitions From Hospital for Older Adults With Fractures N/A
Completed NCT04532580 - Clinical Validation of Boneview for FDA Submission
Completed NCT04237454 - Thermal Imaging Compared to Skeletal Survey in Children Below 2 Years N/A
Recruiting NCT05002335 - Clinical and Radiological Outcomes of Medacta Shoulder System (BE)
Completed NCT02591043 - Surgical Treatment of Low Energy Pelvic Fractures in the Elderly N/A
Completed NCT02933359 - Osteogenic Profiling of Normal Calvarial Bone
Completed NCT01049191 - Bone Microarchitecture in Women With and Without Fracture N/A
Completed NCT03431857 - Multi Centre Study on TESS V2 Shoulder System
Recruiting NCT04133103 - Early Mobilisation in the Surgical Robot Assisted Spinal Surgery N/A
Completed NCT03993691 - Wrist Fracture Evaluation With a Desktop Orthopedic Tomosynthesis System N/A
Active, not recruiting NCT01719887 - Effectiveness and Cost-effectiveness of Surgical Treatment of Humeral Shaft Fractures. Randomized Controlled Trial N/A